ArticleNPJ vaccines2026
Plasmablast, memory B cell and T follicular helper cell responses after human papillomavirus vaccination: effect of dose number and age.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Multiple doses of HPV vaccines induce durable, antibody-mediated protection against HPV infections and HPV-associated diseases. Although actual protection against disease by a single HPV vaccination dose has not been confirmed in randomised trials, this regimen induces protection against incident and persistent HPV infection, similar to multi-dose schedules. However, the cellular mechanisms driving durable antibody responses to subunit vaccines remain poorly understood. B cells and T follicular helper (Tfh) cells play central roles in long-term antibody-mediated immunity. We characterised plasmablast, memory B cell (Bmem), and Tfh cell responses to assess the effects of dose number and age following HPV vaccination in Gambian females aged 4-26 years. A significant induction of HPV16/18-specific IgM plasmablasts occurred after the first dose, while robust HPV16/18-specific IgG plasmablast, Bmem, and Tfh responses were observed after two or three doses. Activation within the total Tfh pool increased with decreasing age, whereas HPV16/18-specific Tfh activation was higher in older vaccinees. These findings demonstrate the potential of multi-dose HPV vaccination schedules to sustain antibody protection through coordinated B cell and Tfh responses and highlight the need for continued monitoring of single-dose regimen. Exploring HPV vaccination in children under nine years may improve delivery and uptake.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.